JP2022548575A5 - - Google Patents
Info
- Publication number
- JP2022548575A5 JP2022548575A5 JP2022515966A JP2022515966A JP2022548575A5 JP 2022548575 A5 JP2022548575 A5 JP 2022548575A5 JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022548575 A5 JP2022548575 A5 JP 2022548575A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ofatumumab
- disease
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025159217A JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196789 | 2019-09-11 | ||
| EP19196789.2 | 2019-09-11 | ||
| EP20154736.1 | 2020-01-30 | ||
| EP20154736 | 2020-01-30 | ||
| PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159217A Division JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548575A JP2022548575A (ja) | 2022-11-21 |
| JP2022548575A5 true JP2022548575A5 (enExample) | 2023-09-13 |
| JP7794735B2 JP7794735B2 (ja) | 2026-01-06 |
Family
ID=72709332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515966A Active JP7794735B2 (ja) | 2019-09-11 | 2020-09-10 | 切替え療法によるｒｍｓの治療 |
| JP2025159217A Pending JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159217A Pending JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220298253A1 (enExample) |
| EP (2) | EP4230655A3 (enExample) |
| JP (2) | JP7794735B2 (enExample) |
| KR (1) | KR20220062025A (enExample) |
| CN (3) | CN114401742B (enExample) |
| AU (1) | AU2020344154A1 (enExample) |
| CA (1) | CA3150947A1 (enExample) |
| DK (1) | DK3864053T3 (enExample) |
| ES (1) | ES2957112T3 (enExample) |
| FI (1) | FI3864053T3 (enExample) |
| IL (1) | IL290619A (enExample) |
| LT (1) | LT3864053T (enExample) |
| MX (1) | MX2022003010A (enExample) |
| SI (1) | SI3864053T1 (enExample) |
| WO (1) | WO2021048280A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| EP4707302A2 (en) * | 2020-04-09 | 2026-03-11 | Novartis AG | Ofatumumab for treating ms while maintaining serum igg |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
-
2020
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 CN CN202410529206.7A patent/CN118436777A/zh active Pending
- 2020-09-10 CN CN202410529209.0A patent/CN118403156A/zh active Pending
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en not_active Ceased
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
- 2020-09-10 JP JP2022515966A patent/JP7794735B2/ja active Active
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko active Pending
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
-
2025
- 2025-09-25 JP JP2025159217A patent/JP2026016387A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548575A5 (enExample) | ||
| LÉmann et al. | Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial | |
| Egan et al. | Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine | |
| AU2013205648B2 (en) | Combination treatment | |
| JP2024102099A5 (enExample) | ||
| JP2022514194A5 (enExample) | ||
| CN113288891A (zh) | 治疗多发性硬化症的组合疗法 | |
| JP7794735B2 (ja) | 切替え療法によるｒｍｓの治療 | |
| JP2024178420A5 (enExample) | ||
| JP2005515214A5 (enExample) | ||
| JP5837877B2 (ja) | 静脈内投与イブプロフェンを用いた患者の治療 | |
| Zeng et al. | LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study | |
| JP2023538065A5 (enExample) | ||
| Wroe | Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis | |
| JP2019178177A5 (enExample) | ||
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| JP2013500964A (ja) | 静脈内イブプロフェンを用いた重篤な病気の患者の治療 | |
| WO2024104290A1 (en) | Method for treating multiple sclerosis | |
| Delmendo et al. | Current strategies in the treatment of multiple sclerosis | |
| JP2021121603A (ja) | 多発性硬化症を処置するための併用療法 | |
| van Riel et al. | Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis | |
| RU2024108530A (ru) | Lou064 для лечения рассеянного склероза | |
| HK40123216A (zh) | 一种治疗多发性硬化症的方法 | |
| TW202535928A (zh) | 治療化膿性汗腺炎之方法 |